Related Experiment Video
Updated: Jun 12, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
[Etanercept in childhood psoriasis]
1Servicio de Dermatología, Hospital de Basurto, Bilbao, Vizcaya, España.
Actas Dermo-Sifiliograficas
|May 25, 2010
Summary
Etanercept effectively treated a 10-year-old boy with severe, treatment-resistant psoriasis. This biological drug is now the first and only approved therapy for children with severe psoriasis in Europe.
Area of Science:
- Pediatric Dermatology
- Immunology
- Pharmacology
Background:
- Severe pediatric psoriasis presents significant challenges due to limited treatment options.
- Psoriasis in children can be debilitating, impacting quality of life and requiring effective therapies.
Observation:
- A 10-year-old male with severe, incapacitating psoriasis, refractory to multiple conventional treatments, was evaluated.
- The patient presented with a long-standing history of psoriasis unresponsive to various therapeutic modalities.
Findings:
- Successful treatment of severe pediatric psoriasis was achieved using etanercept.
- Etanercept demonstrated significant efficacy in managing treatment-resistant psoriasis in a pediatric patient.
Implications:
- Etanercept is now the first and only biological drug authorized for severe psoriasis in the pediatric population in Europe.
- This case highlights the potential of etanercept as a crucial therapeutic option for children and adolescents suffering from severe psoriasis.
Related Concept Videos
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:19Clinical Applications of Epidermal Stem Cells
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...